CLINICAL RESEARCH
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Osteoarthritis of the hip or knee has been reported to be linked to an increased risk of frailty. However, a definitive conclusion about whether hip or knee osteoarthritis increases susceptibility to frailty remains elusive.

Material and methods:
The instrumental variables (IVs) used in this analysis were sourced from publicly available genome-wide association study (GWAS) datasets. We used a two-sample Mendelian randomization analysis to evaluate the plausible causal nexus between hip or knee osteoarthritis and frailty.

Results:
We included a total of 25 single-nucleotide polymorphisms (SNPs) as instrumental variables through rigorous and comprehensive screening. The results of this analysis suggested that hip or knee osteoarthritis is associated with an elevated risk of frailty. These results remained robust and consistent across multiple calculation methods, including inverse variance weighted (OR = 1.082, 95% CI: 1.0532–1.1125, p = 1.36 × 10–8), MR‒Egger regression (OR = 1.175, 95% CI: 1.0162–1.3604, p = 0.040), weighted median estimation (OR = 1.078, 95% CI: 1.0365–1.1219, p = 1.831 × 10–4), weighted mode analysis (OR = 1.089, 95% CI: 1.0078–1.1771, p = 0.041) and simple mode analysis (OR = 1.093, 95% CI: 1.0112–1.1830, p = 0.034). Cochran’s Q test showed no evidence of heterogeneity among the IV estimates derived from individual variants, and the MR‒Egger regression analysis indicated that the presence of horizontal pleiotropy was unlikely to introduce bias into the results (intercept: –0.0044, p = 0.549).

Conclusions:
Two-sample Mendelian randomization analysis effectively identified hip or knee osteoarthritis as a contributing risk factor for frailty.

 
REFERENCES (32)
1.
Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet 2013; 381: 752-62.
 
2.
Dent E, Martin F C, Bergman H, et al. Management of frailty: opportunities, challenges, and future directions. Lancet 2019; 394: 1376-86.
 
3.
Hoogendijk EO, Afilalo J, Ensrud KE, et al. Frailty: implications for clinical practice and public health. Lancet 2019; 394: 1365-75.
 
4.
Mondor L, Maxwell CJ, Hogan DB, et al. The incremental health care costs of frailty among home care recipients with and without dementia in Ontario, Canada: a cohort study. Med Care 2019; 57: 512-20.
 
5.
Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014; 73: 1323-30.
 
6.
Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lacet 2019; 393: 1745-59.
 
7.
Meessen J, Leichtenberg CS, Tilbury C, et al. Frailty in end-stage hip or knee osteoarthritis: validation of the Groningen Frailty Indicator (GFI) questionnaire. Rheum Int 2018; 38: 917-24.
 
8.
Castell MV, Van Der Pas S, Otero A, et al. Osteoarthritis and frailty in elderly individuals across six European countries: results from the European Project on OSteoArthritis (EPOSA). BMC Musculoskel Disord 2015; 16: 359.
 
9.
Cisternas MG, Murphy L, Sacks JJ, et al. Alternative methods for defining osteoarthritis and the impact on estimating prevalence in a US population-based survey. Arthritis Care Res 2016; 68: 574-80.
 
10.
Burgess S, Davey Smith G, Davies NM, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res 2019; 4: 186.
 
11.
Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement. JAMA 2021; 326: 1614-21.
 
12.
Tachmazidou I, Hatzikotoulas K, Southam L, et al. Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data. Nat Genet 2019; 51: 230-6.
 
13.
Atkins JL, Jylhävä J, Pedersen NL, et al. A genome-wide association study of the frailty index highlights brain pathways in ageing. Aging Cell 2021; 20: e13459.
 
14.
Sekula P, Del Greco MF, Pattaro C, et al. Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol 2016; 27: 3253-65.
 
15.
Abecasis GR, Altshuler D, Auton A, et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-73.
 
16.
Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol 2017; 32: 377-89.
 
17.
Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013; 37: 658-65.
 
18.
Mazidi M, Shekoohi N, Katsiki N, et al. Serum anti-inflammatory and inflammatory markers have no causal impact on telomere length: a Mendelian randomization study. Arch Med Sci 2021; 17: 739-51.
 
19.
Huang G, Qian D, Liu Y, et al. The association between frailty and osteoarthritis based on the NHANES and Mendelian randomization study. Arch Med Sci 2023; 19: 1545-50.
 
20.
Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol 2013; 42: 1497-501.
 
21.
O’brien MS, Mcdougall JJ. Age and frailty as risk factors for the development of osteoarthritis. Mechanisms Ageing Development 2019; 180: 21-8.
 
22.
Wise BL, Parimi N, Zhang Y, et al. Frailty and hip osteoarthritis in men in the MrOS cohort. J Gerontol A Biol Sci Med Sci 2014; 69: 602-8.
 
23.
Salmon JH, Rat AC, Sellam J, et al. Economic impact of lower-limb osteoarthritis worldwide: a systematic review of cost-of-illness studies. Osteoarthritis Cartilage 2016; 24: 1500-8.
 
24.
Biritwum RB, Minicuci N, Yawson AE, et al. Prevalence of and factors associated with frailty and disability in older adults from China, Ghana, India, Mexico, Russia and South Africa. Maturitas 2016; 91: 8-18.
 
25.
Misra D, Felson DT, Silliman RA, et al. Knee osteoarthritis and frailty: findings from the Multicenter Osteoarthritis Study and Osteoarthritis Initiative. J Gerontol A Biol Sci Med Sci 2015; 70: 339-44.
 
26.
Veronese N, Maggi S, Trevisan C, et al. Pain increases the risk of developing frailty in older adults with osteoarthritis. Pain Medicine 2017; 18: 414-27.
 
27.
Sibille KT, Chen H, Bartley EJ, et al. Accelerated aging in adults with knee osteoarthritis pain: consideration for frequency, intensity, time, and total pain sites. Pain Rep 2017; 2: e591.
 
28.
Martin JA, Buckwalter JA. Telomere erosion and senescence in human articular cartilage chondrocytes. J Gerontol A Biol Sci Med Sci 2001; 56: B172-9.
 
29.
Waszczykowski M, Fabiś-Strobin A, Bednarski I, et al. Serum and synovial fluid concentrations of interleukin-18 and interleukin-20 in patients with osteoarthritis of the knee and their correlation with other markers of inflammation and turnover of joint cartilage. Arch Med Sci 2022; 18: 448-58.
 
30.
Qiao YQ, Jiang PF, Gao YZ. Lutein prevents osteoarthritis through Nrf2 activation and downregulation of inflammation. Arch Med Sci 2018; 14: 617-24.
 
31.
Zhai G, Aviv A, Hunter DJ, et al. Reduction of leucocyte telomere length in radiographic hand osteoarthritis: a population-based study. Ann Rheum Dis 2006; 65: 1444-8.
 
32.
Rose J, Söder S, Skhirtladze C, et al. DNA damage, discoordinated gene expression and cellular senescence in osteoarthritic chondrocytes. Osteoarthritis Cartilage 2012; 20: 1020-8.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top